Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Par Pharma launch Cortisporin-TC otic suspension to treat otitis externa
Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., announced the launch of Cortisporin-TC otic suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension).
- Read more about Effect of Soy Isoflavone Supplement on Poorly Controlled Asthma
A new study says Soy supplements does not improve lung function for patients with asthma. This study is contrary to previous findings suggesting a link between soy intake and decreased asthma severity.
- Read more about Glenmark receive USFDA approval to sell Rufinamide
Glenmark Pharmaceuticals granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.
- Read more about DeNovo associate with START to use CTCs for whole genome sequencing
DeNovo Sciences, Inc., an innovator of cutting edge products of liquid biopsy, sign an agreement with START (South Texas Accelerated Research Therapeutics), a San Antonio based phase I medical oncology programme, one of the world’s largest of its kind with clinical trial sites on three continents. As per agreement, START will collect blood samples of cancer patients and use DeNovo instruments and reagents for circulating tumour cells (CTC) enrichment and purification. This will further will then be sent to a large genomics lab for whole genome sequencing. In addition, START and DeNovo have signed a separate agreement to test the ability of Denovo CTC platform to capture CTCs for use in patient derived xenograft (PDX) mice models for drug discovery and biomarker development purposes.
- Read more about Drugs may withdrawn from Indian market if they banned in other countries
Drugs Controller General India (DCGI) has issued a notice in observance of the compliance for patient safety which seems more appealing and beneficial. DCGI notified to drug importers that they will inform or report to Indian authorities about time to time regulatory actions taken on their drugs in different countries where drugs are sold or distributed.
- Read more about 19 pharma companies received final warning from NPPA for registeration with IPDMS
National Pharmaceutical Pricing Authority (NPPA) given a final opportunity to companies to register with Integrated Pharmaceutical Database Management System (IPDMS). 19 companies out of Top 100, which have not yet registered with IPDMS as on 01.06.2015.
- Read more about 11PC pepole in delhi suffering from asthma: Nadda
Around 11 per cent of the people in Delhi are suffering from asthma the government said while attributing its causes to smoking and air pollution.
- Read more about Bio-Medical waste generation UP by 16 PC; K'TAKA top producer
There has been a 16 per cent increase in daily generation of bio-medical waste in 2012-13 as against a marginal increase of 0.33 per cent the year ago, Lok Sabha was informed. Karnataka was the highest producer of bio-waste at 83,614 kg per day, followed by Maharashtra, which produced 65,660 kg of bio-wastes every day.
- Read more about Decreased Sexual Activity in Women following Treatment for Gynecologic Cancers
In the United States every year nearly 90,000 women are diagnosed with some gynecological cancer. These include cancer of the cervix, uterus, ovaries, vagina, and vulva. These women undergo treatments including radiation, chemotherapy and surgery. A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 has shown sexual dysfunction in women following gynecologic cancer treatment. The study shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.

[adsense:336x280:8701650588]
- Read more about Vanda Pharma honoured with 2015 Industry Innovation Award from NORD for development of Hetlioz
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs., has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of company's work in developing Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). This award was presented to Vanda at the 2015 Portraits of Courage Gala in Washington D.C. on 18th May.